| pubmed-article:21576633 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0242596 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1521828 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1722284 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C0439590 | lld:lifeskim |
| pubmed-article:21576633 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:21576633 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:21576633 | pubmed:dateCreated | 2011-6-20 | lld:pubmed |
| pubmed-article:21576633 | pubmed:abstractText | Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective lysis of tumor cells. In acute lymphoblastic leukemia (ALL), persistence or relapse of minimal residual disease (MRD) after chemotherapy indicates resistance to chemotherapy and results in hematologic relapse. A phase II clinical study was conducted to determine the efficacy of blinatumomab in MRD-positive B-lineage ALL. | lld:pubmed |
| pubmed-article:21576633 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21576633 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21576633 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21576633 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21576633 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21576633 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:KuferPeterP | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:RiethmüllerGe... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:EinseleHerman... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:HoelzerDieter... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:GökbugetNicol... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:OttmannOliver... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:ZugmaierGerha... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:NagorsenDirkD | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:BaeuerlePatri... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:SchaichMarkus... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:KnebaMichaelM | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:KlingerMatthi... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:ToppMax SMS | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:BargouRalf... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:PfeiferHeikeH | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:ViardotAndrea... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:RaffThorstenT | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:Köhne-Volland... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:NeumannSvenja... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:StelljesMatth... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:SchmidMathias... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:SchmidtMargit... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:BrüggemannMon... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:BurmeisterTho... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:LutterbueseRa... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:ReinhardtCars... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:GoebelerMarie... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:HorstHeinz-AH... | lld:pubmed |
| pubmed-article:21576633 | pubmed:author | pubmed-author:DegenhardEvel... | lld:pubmed |
| pubmed-article:21576633 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21576633 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:21576633 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:21576633 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21576633 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21576633 | pubmed:pagination | 2493-8 | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:meshHeading | pubmed-meshheading:21576633... | lld:pubmed |
| pubmed-article:21576633 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21576633 | pubmed:articleTitle | Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. | lld:pubmed |
| pubmed-article:21576633 | pubmed:affiliation | Comprehensive Cancer Center Mainfranken, University Wuerzburg, Germany. | lld:pubmed |
